APA (7th ed.) Citation

Y, C., T, Q., C, C., F, B. B., & G, B. (2025). Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: Patient-reported outcomes in the RATIONALE-312 trial. Current medical research and opinion, 41(12), 2357. https://doi.org/10.1080/03007995.2026.2620691

Chicago Style (17th ed.) Citation

Y, Cheng, Qin T, Chen C, B Barnes F, and Barnes G. "Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-line Treatment for Extensive-stage Small-cell Lung Cancer: Patient-reported Outcomes in the RATIONALE-312 Trial." Current Medical Research and Opinion 41, no. 12 (2025): 2357. https://doi.org/10.1080/03007995.2026.2620691.

MLA (9th ed.) Citation

Y, Cheng, et al. "Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-line Treatment for Extensive-stage Small-cell Lung Cancer: Patient-reported Outcomes in the RATIONALE-312 Trial." Current Medical Research and Opinion, vol. 41, no. 12, 2025, p. 2357, https://doi.org/10.1080/03007995.2026.2620691.